编者按:2026年9月16日~19日,第29届中国临床肿瘤学会(CSCO)学术年会在济南召开,汇聚全球肿瘤领域精英,共探精准诊疗创新发展路径。国际恶性淋巴瘤会议(ICML)主席、瑞士贝林佐纳肿瘤研究所Franco Cavalli教授受邀参会并发表专题报告。作为长期深耕肿瘤学领域的国际知名专家,Cavalli教授自1989年首次到访中国以来,见证了中国肿瘤学三十余年的发展变迁。在接受《肿瘤瞭望-血液时讯》采访时,他回顾了与中国肿瘤学交流合作的历程与感悟,分享了结外淋巴瘤领域的重要进展与未来探索方向,并前瞻介绍了ICML 2027值得关注的重点议题。
《肿瘤瞭望-血液时讯》:欢迎您来到中国参加2026 CSCO学术年会。作为长期致力于肿瘤学研究与国际学术交流的专家,您如何评价中国肿瘤领域近年来的发展与进步?此次参会期间,您有哪些特别的感受与期待?
Franco Cavalli教授:我首次到访中国是在1989年。此后,我参加了2005年在青岛举办的CSCO学术年会。在我看来,中国肿瘤学领域的发展轨迹,与中国其他各领域的变革如出一辙。1989年我初次到访,十年后再度来访时,几乎已认不出这个国家——它发生了翻天覆地的变化。肿瘤学领域亦然。初次来访时,我的印象是,这里作为发展中国家,人们对现代癌症治疗知之甚少。而十年之后,情况已截然不同,同行们的专业认知显著提升,内科肿瘤学在此期间取得了长足进步。
如今,中国在肿瘤学诸多方面的进展已跻身世界前沿。二十五年前,这里仅有西方制药企业的身影;而今,中国本土制药企业已与西方企业并驾齐驱,甚至更具创新性。当前,大量Ⅲ期临床试验的新临床数据来自中国。在将人工智能应用于癌症研究方面,中国同样处于领先地位。我们正与重庆的徐波教授筹备签署谅解备忘录,以推进该领域的合作。毋庸置疑,中国在开发高度创新的疗法方面已走在前列,以CAR-T细胞疗法为例,多发性骨髓瘤CAR-T疗法的首批临床数据便源自中国。目前,通过将传统方法与各类白细胞介素相结合以提升CAR-T细胞疗效的新策略,也正在中国研发之中。
可以说,二十五年前,我们参加CSCO年会旨在传授经验;而今天,我们参会更多是为了学习借鉴。
Oncology Frontier-Hematology Frontier:Welcome to China for the 2026 CSCO Annual Meeting. As an expert who has been dedicated to oncology research and international academic collaboration for many years, how do you evaluate the recent development and progress of oncology in China? During this visit, what are your special impressions and expectations?
Professor Franco Cavalli:My first visit to China was in 1989. Subsequently, I attended the CSCO Annual Meeting held in Qingdao in 2005. In my view, the developmental trajectory of oncology in China mirrors the transformation seen across all other sectors. When I first arrived in 1989 and returned a decade later, the country was almost unrecognizable, having undergone earth-shattering changes. The field of oncology followed a similar path. During my initial visit, my impression was that of a developing nation where modern cancer therapeutics were little understood. Ten years on, the landscape had changed drastically; professional awareness among peers had improved significantly, and medical oncology had made substantial progress during that interval.
Today, China stands at the forefront of global advancements in numerous aspects of oncology. Twenty-five years ago, the pharmaceutical landscape was dominated exclusively by Western companies. Now, domestic Chinese pharmaceutical enterprises stand on equal footing with their Western counterparts, and arguably demonstrate greater innovation. Currently, a significant volume of new clinical data from Phase III trials originates from China. China is also leading the way in applying artificial intelligence to cancer research. We are currently preparing a memorandum of understanding with Professor Xu Bo from Chongqing to foster collaboration in this field. There is no doubt that China is at the vanguard of developing highly innovative therapies. Taking CAR-T cell therapy as an example, the initial clinical data for CAR-T therapy in multiple myeloma originated from China. At present, novel strategies combining traditional approaches with various interleukins to enhance the efficacy of CAR-T cells are also under development in China.
It can be said that twenty-five years ago, we attended the CSCO Annual Meeting to teach; today, we attend primarily to learn.
《肿瘤瞭望-血液时讯》:在淋巴瘤专场中,您围绕“What's New in Extranodal Lymphoma”进行了专题报告。近年来,结外淋巴瘤在分子分型、精准诊疗以及治疗策略方面不断取得进展。能否请您介绍当前该领域有哪些重要突破?未来研究还面临哪些关键挑战?
Franco Cavalli教授:三十年前,我们决定成立国际结外淋巴瘤研究组(IELSG)。在结外淋巴瘤中,发病部位是最重要的预后因素,因此必须对乳腺、肝脏、中枢神经系统、胃等各个部位进行单独研究。然而,世界上没有任何一家机构拥有足够的病例来完成这项工作,唯有通过合作组才能实现。因此,我们创建了该研究组,如今已涵盖三百余家机构。
基于这一合作平台,我们逐步完善了对各部位结外淋巴瘤自然病程的认知。随后,我们开展了多项前瞻性研究,并据此重新定义了大多数部位的标准治疗方案。其中最重要的进展包括:证实原发性纵隔淋巴瘤不再需要放射治疗;原发性中枢神经系统淋巴瘤通过现代化学疗法联合自体骨髓移植,同样可避免放疗——尽管该病在过去几乎总是致命的,如今至少有50%的患者可以获得治愈。我们还证实,在睾丸淋巴瘤中,可以有效预防中枢神经系统复发,而过去其发生率超过50%。此外,我们证实仅通过根除幽门螺杆菌即可治愈大多数胃MALT淋巴瘤。
目前,我们正致力于深入探究不同结外淋巴瘤亚型的分子生物学特征及其微环境组成,以期更好地表征一些尚未被充分定义的亚型。尽管我们已重新定义了几乎所有部位结外淋巴瘤的治疗方案,但我们仍在不断前行,以进一步了解各部位的生物学基础,最终目标是实现所有患者的治愈。
Oncology Frontier-Hematology Frontier:During the lymphoma session, you delivered a presentation entitled “What’s New in Extranodal Lymphoma.” In recent years, significant advances have been achieved in the molecular classification, precision diagnosis and treatment, and therapeutic strategies for extranodal lymphoma. Could you please share the most important breakthroughs in this field? What are the key challenges that future research needs to address?
Professor Franco Cavalli:Thirty years ago, we decided to establish the International Extranodal Lymphoma Study Group (IELSG). In extranodal lymphomas, the site of involvement is the most important prognostic factor; therefore, each site—such as the breast, liver, central nervous system, and stomach—must be studied individually. However, no single institution worldwide possesses a sufficient number of cases to conduct such studies independently; this is feasible only through a collaborative group. Consequently, we established this study group, which now encompasses more than 300 institutions.
Building upon this collaborative platform, we have progressively refined our understanding of the natural history of extranodal lymphomas at various sites. Subsequently, we conducted multiple prospective studies, based on which we have redefined the standard treatment regimens for most sites. The most significant advances include: demonstrating that radiation therapy is no longer required for primary mediastinal lymphoma; and showing that primary central nervous system (CNS) lymphoma can also be managed without radiotherapy through modern chemotherapy combined with autologous bone marrow transplantation. Although this disease was almost invariably fatal in the past, at least 50% of patients can now be cured. We have further demonstrated that CNS relapse in testicular lymphoma, which previously occurred in over 50% of cases, can now be effectively prevented. Additionally, we have confirmed that the majority of gastric MALT lymphomas can be cured solely through Helicobacter pylori eradication.
Currently, we are dedicated to exploring in depth the molecular biological characteristics and microenvironment composition of different extranodal lymphoma subtypes, with the aim of better characterizing those subtypes that are not yet fully defined. Although we have redefined treatment protocols for extranodal lymphomas at nearly all sites, we continue to advance our efforts to further elucidate the biological foundations of each site, with the ultimate goal of achieving a cure for all patients.
《肿瘤瞭望-血液时讯》:第19届国际恶性淋巴瘤大会(ICML 2027)将于2027年6月15日至19日在瑞士卢加诺举行。作为ICML的重要推动者,您如何介绍本届大会的特色与重点关注方向?对于即将参加ICML 2027的中国专家学者,您有哪些期待与寄语?
Franco Cavalli教授:目前,会议的核心议题已初步确定。当然,最终议程将取决于明年收到的约1500份摘要,这些摘要将带来多少创新成果,我们尚无法预判。但正如往届ICML会议一样,正式会议前一天将举办一场研讨会,聚焦当下最热门的话题。本次研讨会的主题是:统一并明确液体活检及ctDNA在制定淋巴瘤患者治疗方案中的精确作用。借助PET与ctDNA技术,我们已在部分淋巴瘤中实现了治疗的个体化与精准化。我们的期望是,未来能够基于ctDNA和PET为所有患者制定个体化治疗方案,这将成为本次会议最受关注的议题之一。
另一个对中国参会者而言至关重要的议题,是ICML与中国淋巴瘤研究者联盟(Union of Chinese Lymphoma Investigators)联合举办的特别会议。该会议将聚焦基因治疗与CAR-T细胞治疗,重点讨论适应证的统一、监管标准的统一以及临床试验规则的统一。基因治疗领域目前仍存在诸多挑战,因此我们将对比欧洲与中国在监管与规则方面的经验,以推动淋巴瘤基因治疗与T细胞治疗的进一步发展。
第三个极具前沿性的议题是,会议将安排多场关于基因新知识的专题演讲。目前,我们对DNA非编码区域的了解仍然有限,然而从数量上看,非编码区域是DNA中最重要的组成部分,很可能在定义不同淋巴瘤亚型的生物学特性方面发挥关键作用。围绕这一主题,会议将展开大量深入讨论。
以上三个议题是我目前能够预见的最重要内容。当然,基于我们将收到的摘要,届时还将涌现许多其他议题,期待大家的持续关注。
Oncology Frontier-Hematology Frontier:The 19th International Conference on Malignant Lymphoma (ICML 2027) will be held in Lugano, Switzerland, from June 15 to 19, 2027. As one of the key figures involved in the development of ICML, how would you introduce the highlights and major topics of this upcoming meeting? What expectations and messages would you like to share with Chinese experts and researchers who will participate in ICML 2027?
Professor Franco Cavalli:The core agenda of the conference has been tentatively established. Of course, the final program will depend on the approximately 1,500 abstracts we expect to receive next year; it remains to be seen how many innovative findings these submissions will yield. However, as is customary for previous ICML meetings, a symposium focusing on the most pressing current topics will be held the day before the official conference. The theme of this symposium is to harmonize and define the precise role of liquid biopsy and circulating tumor DNA (ctDNA) in guiding treatment decisions for patients with lymphoma. By leveraging PET and ctDNA technologies, we have already achieved individualized and precision therapy in certain lymphoma subtypes. Our aspiration is to reach a stage where individualized treatment plans can be formulated for all patients based on ctDNA and PET findings, which will undoubtedly be one of the most anticipated topics of this meeting.
Another agenda item of particular significance to Chinese attendees is the special session jointly organized by the ICML and the Union of Chinese Lymphoma Investigators. This session will focus on gene therapy and CAR-T cell therapy, with an emphasis on harmonizing indications, regulatory standards, and clinical trial protocols. Given the existing challenges in the field of gene therapy, we will compare regulatory frameworks and operational experiences between Europe and China to further advance the development of gene therapy and T-cell therapy for lymphoma.
The third highly cutting-edge topic involves a series of special lectures on emerging genetic insights. Currently, our understanding of the non-coding regions of DNA remains limited. However, in terms of quantity, these non-coding regions constitute the most substantial component of DNA and are likely to play a pivotal role in defining the biological characteristics of different lymphoma subtypes. Extensive in-depth discussions on this subject are scheduled for the conference.
These three topics represent the most significant themes I can currently anticipate. Naturally, based on the abstracts we will receive, many other compelling topics will emerge, and we look forward to your continued attention.
专家简介
Franco Cavalli教授
瑞士贝林佐纳肿瘤研究所
国际抗癌联盟(UICC)前任主席
瑞士医学科学院院士
瑞士南部贝林佐纳肿瘤研究所(IOSI)的科研主任
瑞士癌症联盟瑞士临床研究小组(SAKK)前主席
欧洲肿瘤学院(ESO)及世界肿瘤学论坛(WOF)学术委员会主席
国际恶性淋巴瘤会议(ICML)主席
国际结外淋巴瘤研究组(IELSG)主席
发表了600多篇文章,并参与多部癌症书籍的编纂
曾获肿瘤学国际奖项20余项
美国癌症研究学会癌症研究(AACR)终身成就奖